Journal of Nuclear Medicine · 2019 · 94 citations · 14 references
MedicineNuclear MedicineOncologyDiagnostic ImagingDiagnostic Nuclear MedicineDiagnostic RadiologyHepatobiliary ImagingPositron Emission TomographyProstate CancerProstate Cancer ImagingRenal Nuclear ImagingTumor ImagingOncologic Pet ImagingProstate Cancer DiagnosisProstate-specific Antigen Test PerformanceProstate-specific Membrane Antigen PetProstate-specific Membrane Antigen Positron Emission TomographyProstate-specific Membrane Antigen RadioligandsPsma Targeting LigandsPsma-pet Imaging
<sup>18</sup>F-prostate-specific membrane antigen (PSMA)-1007 is excreted mainly through the liver. We benchmarked the performance of <sup>18</sup>F-PSMA-1007 against 3 renally excreted PSMA tracers. <b>Methods:</b> Among 668 patients, we selected 27 in whom PET/CT results obtained with <sup>68</sup>Ga-PSMA-11, <sup>18</sup>F-DCFPyL (2-(3-(1-carboxy-5-[(6-[<sup>18</sup>F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid), or <sup>18</sup>F-JK-PSMA-7 (JK, Juelich-Koeln) were interpreted as equivocal or negative or as oligometastatic disease (PET-1). Within 3 wk, a second PET scan with <sup>18</sup>F-PSMA-1007 was performed (PET-2). The confidence in the interpretation of PSMA-positive locoregional findings was scored on a 5-point scale, first in routine diagnostics (reader 1) and then by an independent second evaluation (reader 2). Discordant PSMA-positive skeletal findings were examined by contrast-enhanced MRI. <b>Results:</b> For both readers, <sup>18</sup>F-PSMA-1007 facilitated the interpretability of 27 locoregional lesions. In PET-2, the clinical readout led to a significantly lower number of equivocal locoregional lesions (<i>P</i> = 0.024), and reader 2 reported a significantly higher rate of suspected lesions that were falsely interpreted as probably benign in PET-1 (<i>P</i> = 0.023). Exclusively in PET-2, we observed a total of 15 PSMA-positive spots in the bone marrow of 6 patients (22%). None of the 15 discordant spots had a morphologic correlate on the corresponding CT scan or on the subsequent MRI scan. Thus, <sup>18</sup>F-PSMA-1007 exhibits a significantly higher rate of unspecific medullary spots (<i>P</i> = 0.0006). <b>Conclusion:</b><sup>18</sup>F-PSMA-1007 may increase confidence in interpreting small locoregional lesions adjacent to the urinary tract but may decrease the interpretability of skeletal lesions.
14
Frederik L. Giesel, Boris Hadaschik, Jens Cardinale et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 602 citations · Full text
Ying Chen, Mrudula Pullambhatla, Catherine A. Foss et al. · Clinical Cancer Research · 2011 · 399 citations · Full text
Medicine, Nuclear Medicine, Oncology +17